MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414284 | Name: L 659066

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L 659066 has been characterized as a potent and selective alpha-2 adrenoceptor antagonist.

Chemical Structure

L 659066
L 659066
CAS#114914-42-0

Theoretical Analysis

MedKoo Cat#: 414284

Name: L 659066

CAS#: 114914-42-0

Chemical Formula: C20H26N4O4S

Exact Mass: 418.1675

Molecular Weight: 418.51

Elemental Analysis: C, 57.40; H, 6.26; N, 13.39; O, 15.29; S, 7.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
L 659066; L659066; L-659066; MK 467; MK467; MK-467
IUPAC/Chemical Name
Methanesulfonamide, N-(2-(1,3,4,6,7,12b-hexahydro-2'-oxospiro(2H-benzofuro(2,3-a)quinolizine-2,4'-imidazolidin)-3'-yl)ethyl)-, trans-
InChi Key
GTBKISRCRQUFNL-UZLBHIALSA-N
InChi Code
InChI=1S/C20H26N4O4S/c1-29(26,27)22-8-11-24-19(25)21-13-20(24)7-10-23-9-6-15-14-4-2-3-5-17(14)28-18(15)16(23)12-20/h2-5,16,22H,6-13H2,1H3,(H,21,25)/t16-,20+/m1/s1
SMILES Code
CS(=O)(NCCN([C@@]1(CN2)CCN3CCC4=C(OC5=CC=CC=C54)[C@@]3([H])C1)C2=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 418.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Raekallio MR, Honkavaara JM, Vainio OM. The effects of L-659,066, a peripheral α2-adrenoceptor antagonist, and verapamil on the cardiovascular influences of dexmedetomidine in conscious sheep. J Vet Pharmacol Ther. 2010 Oct;33(5):434-8. doi: 10.1111/j.1365-2885.2009.01156.x. PMID: 20840386. 2: Honkavaara JM, Raekallio MR, Kuusela EK, Hyvärinen EA, Vainio OM. The effects of L-659,066, a peripheral alpha2-adrenoceptor antagonist, on dexmedetomidine- induced sedation and bradycardia in dogs. Vet Anaesth Analg. 2008 Sep;35(5):409-13. doi: 10.1111/j.1467-2995.2008.00403.x. Epub 2008 May 5. PMID: 18466161. 3: Iwanaga S, Shibata O, Tsuda A, Hashimoto S, Makita T, Cho S, Sumikawa K. The role of alpha1-adrenoceptors in the clonidine-induced contraction and relaxation of rat aorta. Res Commun Mol Pathol Pharmacol. 1998 Nov;102(2):137-47. PMID: 10100505. 4: Clineschmidt BV, Pettibone DJ, Lotti VJ, Hucker HB, Sweeney BM, Reiss DR, Lis EV, Huff JR, Vacca J. A peripherally acting alpha-2 adrenoceptor antagonist: L-659,066. J Pharmacol Exp Ther. 1988 Apr;245(1):32-40. PMID: 2896239. 5: Pypendop BH, Ahokoivu H, Honkavaara J. Pharmacokinetics of vatinoxan in male neutered cats anesthetized with isoflurane. Vet Anaesth Analg. 2020 Jan;47(1):70-75. doi: 10.1016/j.vaa.2019.10.004. Epub 2019 Oct 24. PMID: 31806431. 6: Jaeger AT, Pypendop BH, Ahokoivu H, Honkavaara J. Cardiopulmonary effects of dexmedetomidine, with and without vatinoxan, in isoflurane-anesthetized cats. Vet Anaesth Analg. 2019 Nov;46(6):753-764. doi: 10.1016/j.vaa.2019.05.012. Epub 2019 Jun 17. PMID: 31416697. 7: Schafers RF, Elliott HL, Howie CA, Reid JL. A preliminary, clinical pharmacological assessment of L-659,066, a novel alpha 2-adrenoceptor antagonist. Br J Clin Pharmacol. 1992 Dec;34(6):521-6. PMID: 1362887; PMCID: PMC1381454. 8: Pypendop BH, Ahokoivu H, Honkavaara J. Pharmacokinetics of dexmedetomidine during administration of vatinoxan in male neutered cats anesthetized with isoflurane. J Vet Pharmacol Ther. 2020 Jan;43(1):1-5. doi: 10.1111/jvp.12796. Epub 2019 Jul 18. PMID: 31318080. 9: Pypendop BH, Ahokoivu H, Honkavaara J. Effects of dexmedetomidine, with or without vatinoxan (MK-467), on minimum alveolar concentration of isoflurane in cats. Vet Anaesth Analg. 2019 Jul;46(4):443-451. doi: 10.1016/j.vaa.2019.02.004. Epub 2019 Feb 22. PMID: 30982711. 10: Huuskonen V, Restitutti F, Honkavaara JM, Raekallio MR, Männikkö S, Scheinin M, Vainio OM. Investigation of the effects of vatinoxan on somatic and visceral antinociceptive efficacy of medetomidine in dogs. Am J Vet Res. 2020 Apr;81(4):299-308. doi: 10.2460/ajvr.81.4.299. PMID: 32228259.